GlassScriptPhysician profile
Michelle Bridges
NPI 1730427394
$624.35
in general payments reported to CMS, 2019-2025
14 companies · $55.44 in 2025
The $55.44 reported for 2025 was less than what a typical Women'S Health (Nurse Practitioner) provider received nationally (typical 2025 total: $123).
See the full distribution for Women's Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $144 · 2022: $46.39 · 2023: $116 · 2024: $262 · 2025: $55.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $434.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $433.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $156.70 | 2024 | Aptima |
| Otsuka America Pharmaceutical, INC. | $154.12 | 2021-2023 | Rexulti |
| Evofem Biosciences, INC. | $50.68 | 2024 | |
| Mayne Pharma Commercial LLC | $39.16 | 2024 | |
| Astellas Pharma US INC | $38.23 | 2024-2025 | Veozah |
| Corium, LLC | $37.52 | 2023 | Azstarys |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.87 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $19.48 | 2023 | Ingrezza |
| Organon LLC | $17.97 | 2022 | |
| Lilly USA, LLC | $16.86 | 2025 | Mounjaro, Zepbound |
| Ani Pharmaceuticals, INC. | $16.22 | 2025 | Purified Cortrophin Gel |
| Merck Sharp & Dohme LLC | $15.54 | 2021 | |
| Abbvie INC. | $15.48 | 2023 | |
| Supernus Pharmaceuticals, INC. | $12.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Bridges listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.